RED: The British Society for Rheumatology Guideline for the Management of Gout recommend that benzbromarone (and probenecid) are only available for the treatment of patients with gout in the UK on a named patient basis, and patients requiring these unlicensed drugs should be under the care of a Rheumatologist.
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care